查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1574267

DNA 疫苗市場：按類型、應用、最終用戶、交付方法、技術、治療領域、給藥途徑- 2025-2030 年全球預測

DNA Vaccine Market by Type, Application, End-User, Delivery Method, Technology, Therapeutic Area, Route of Administration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年DNA疫苗市值為2.6393億美元，預計2024年將達到3.0254億美元，複合年成長率為13.84%，到2030年將達到6.5423億美元。

DNA疫苗是免疫技術的重要進步，它直接引入基因工程DNA來引發免疫反應。這些疫苗對於對抗傳統疫苗所困擾的疾病至關重要，它們描述了更簡化的生產流程和持續更長時間的廣泛免疫反應。隨著新出現的感染疾病和生物恐怖主義威脅等全球健康挑戰的加劇，DNA疫苗在歷史上一直發揮​​著特殊作用，變得越來越必要。 DNA 疫苗具有廣泛的用途，從人類和動物疫苗到癌症和慢性病的治療，最終用途從個人醫療到公共衛生工作。

主要市場統計
基準年[2023] 26393萬美元
預測年份 [2024] 30254萬美元
預測年份 [2030] 6.5423億美元
複合年成長率（%） 13.84%

推動市場成長的關鍵因素是基因工程技術的進步、研發投入的增加以及逐步適應新療法的法規環境。世界人口老化和預防保健意識的增強進一步推動了市場需求。新興市場存在重要機遇，公共衛生需求推動創新疫苗接種策略的快速採用。公司可以透過投資當地的製造和分銷基礎設施來進入這個市場。

然而，挑戰依然存在，例如高昂的初始研發成本、疫苗穩定性問題以及公眾對基因技術的擔憂。此外，由於司法管轄區的差異而造成的監管障礙也構成了重大風險。同時，技術創新集中在加強電穿孔等疫苗傳輸系統和提高熱穩定性以促進分配。專注於擴大 DNA 疫苗免疫抗原性原性的研究舉措有可能解決現有的限制並擴大其適用性。

DNA疫苗市場正處於起步階段，正在快速發展，因此有必要明確其策略定位。相關人員應優先考慮與生物技術公司和研究機構的合作，以加速創新和市場進入。解決公眾和監管機構接受度的複雜挑戰也很重要。最終，重視技術靈活性和策略夥伴關係關係並能夠靈活應對這些動態的公司可能會在市場格局中取得成功。

市場動態：揭示快速發展的 DNA 疫苗市場的關鍵市場洞察

DNA 疫苗市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 對快速且可擴展的疫苗生產方法的需求不斷成長
    • 加強法規結構以支持 DNA 疫苗的核准和商業化
    • 加強疫苗開發的公私合營
    • 新興市場疫苗接種計劃的擴大推動市場成長
  • 市場限制因素
    • 醫療保健專業人員和患者對 DNA 疫苗技術的認知和接受度較低
    • 確保 DNA 疫苗在目標細胞中的穩定性和傳遞的技術挑戰
  • 市場機會
    • 感染疾病的日益普及需要開發靶向 DNA 疫苗
    • 開發個人化 DNA 疫苗，提供針對個別患者需求的客製化解決方案
    • 遞送技術的進步提高了 DNA 疫苗的功效和可接受性
  • 市場問題
    • 不同地區配送DNA疫苗低溫運輸物流的複雜性
    • DNA疫苗產業研發成本高，新進入壁壘

波特五力：駕馭 DNA 疫苗市場的策略工具

波特的五力框架是了解 DNA 疫苗市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解 DNA 疫苗市場的外部影響

外部宏觀環境因素在塑造 DNA 疫苗市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解DNA疫苗市場的競爭狀況

DNA 疫苗市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣 DNA 疫苗市場供應商的績效評估

FPNV定位矩陣是評估DNA疫苗市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製 DNA 疫苗市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對 DNA 疫苗市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

它也回答重要問題，幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 對快速且可擴展的疫苗生產方法的需求不斷成長
      • 加強法規結構以支持 DNA 疫苗的核准和商業化
      • 加強疫苗開發的公私合營
      • 發展中地區疫苗接種計劃的擴大推動市場成長
    • 抑制因素
      • 醫療保健專業人員和患者對 DNA 疫苗技術的認知和接受度較低
      • 確保 DNA 疫苗穩定性和遞送至目標細胞的技術挑戰
    • 機會
      • 感染疾病的傳播正在擴大，需要開發靶向 DNA 疫苗。
      • 開發個人化 DNA 疫苗，提供針對個別患者需求的客製化解決方案
      • 遞送技術的進步提高了 DNA 疫苗的功效和可接受性
    • 任務
      • 確保不同地區之間運送 DNA 疫苗的低溫運輸物流的複雜性
      • DNA疫苗產業研發成本高，新進入壁壘
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章 DNA 疫苗市場：依類型

  • 介紹
  • 質體DNA疫苗
  • 重組蛋白疫苗
  • 病毒載體疫苗

第7章 DNA疫苗市場：依應用分類

  • 介紹
  • 過敏
  • 感染疾病
  • 瘤

第8章 DNA 疫苗市場：依最終用戶分類

  • 介紹
  • 學術研究所
  • 合約研究組織
  • 製藥公司

第9章 DNA疫苗市場：以交付方式

  • 介紹
  • 基因槍
  • 噴射注射器
  • 無針注射
    • 生物噴射器
    • 電穿孔

第10章 DNA疫苗市場：依技術分類

  • 介紹
  • 電穿孔遞送
  • 基因槍遞送
  • 透過脂質體遞送

第11章 DNA疫苗市場：依治療領域

  • 介紹
  • 過敏
  • 自體免疫疾病
  • 癌症
  • 感染疾病

第12章 DNA 疫苗市場：依給藥途徑

  • 介紹
  • 皮內
  • 肌肉注射
  • 鼻內
  • 皮下的

第13章 美洲DNA疫苗市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第14章亞太DNA疫苗市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第15章 歐洲、中東和非洲DNA疫苗市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第16章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C0154

The DNA Vaccine Market was valued at USD 263.93 million in 2023, expected to reach USD 302.54 million in 2024, and is projected to grow at a CAGR of 13.84%, to USD 654.23 million by 2030.

DNA vaccines represent a significant advancement in immunization technology, involving the direct introduction of genetically engineered DNA to produce an immunological response. These vaccines are crucial in addressing diseases that traditional vaccines may struggle with, offering a more streamlined production process with long-lasting and broad immune responses. Historically niche, their necessity has surged amidst rising global health challenges such as emerging infectious diseases and bioterrorism threats. DNA vaccines exhibit a versatile application scope, from human and veterinary vaccines to cancer and chronic disease treatments, with end-uses extending to personal healthcare and public health initiatives.

KEY MARKET STATISTICS
Base Year [2023] USD 263.93 million
Estimated Year [2024] USD 302.54 million
Forecast Year [2030] USD 654.23 million
CAGR (%) 13.84%

Market growth is primarily influenced by advancements in genetic engineering technologies, increasing R&D investments, and a supportive regulatory environment that's gradually adapting to novel therapeutics. An aging global population and heightened awareness of preventive healthcare further bolster market demand. A pivotal opportunity lies in emerging markets, where public health needs catalyze rapid adoption of innovative vaccination strategies. Companies can capitalize here by investing in localized manufacturing and distribution infrastructures.

Challenges remain, such as high initial R&D costs, issues with vaccine stability, and public apprehension concerning genetic technologies. Regulatory hurdles across different jurisdictions also pose significant risks. Meanwhile, innovation can pivot around enhancing vaccine delivery systems, such as electroporation methods, and improving thermal stability for easier distribution. Research initiatives focusing on expanding the immunogenic profile of DNA vaccines could address existing limitations and broaden applicability.

The DNA vaccine market is both nascent and rapidly evolving, demanding keen strategic positioning. Stakeholders should prioritize collaborations with biotech firms and research institutions to fast-track innovation and market entry. Addressing the complex challenge of public and regulatory acceptance will be critical. Ultimately, companies that navigate these dynamics with agility-emphasizing technological flexibility and strategic partnerships-are likely to thrive in the DNA vaccine market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving DNA Vaccine Market

The DNA Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing need for rapid and scalable vaccine production methodologies
    • Enhanced regulatory frameworks supporting the approval and commercialization of DNA vaccines
    • Increasing collaboration between public and private sectors for vaccine development
    • Expansion of vaccination programs in developing regions boosting market growth
  • Market Restraints
    • Low awareness and acceptance of DNA vaccine technology among healthcare professionals and patients
    • Technical challenges in ensuring the stability and delivery of DNA vaccines in target cells
  • Market Opportunities
    • Rising prevalence of infectious diseases necessitating the development of targeted DNA vaccines
    • Development of personalized DNA vaccines offering tailor-made solutions for individual patient needs
    • Advancements in delivery technologies enhancing the effectiveness and acceptance of DNA vaccines
  • Market Challenges
    • Complexities in ensuring cold chain logistics for the distribution of DNA vaccines across different regions
    • Barriers to market entry for new players due to high research and development costs in the DNA vaccine industry

Porter's Five Forces: A Strategic Tool for Navigating the DNA Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the DNA Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the DNA Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the DNA Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the DNA Vaccine Market

A detailed market share analysis in the DNA Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the DNA Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the DNA Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the DNA Vaccine Market

A strategic analysis of the DNA Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the DNA Vaccine Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bioject Medical Technologies Inc., Emergent BioSolutions, ExcellGene SA, Genentech, Inc., GeneOne Life Science, Inc., GeoVax Labs, Inc., Immunomic Therapeutics, Inc., Inovio Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, OncoSec Medical Incorporated, Profectus BioSciences, Inc., TechnoVax Inc., Vaccibody AS, Vaxess Technologies Inc., and Vical Incorporated.

Market Segmentation & Coverage

This research report categorizes the DNA Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Plasmid DNA Vaccine, Recombinant Protein Vaccine, and Viral Vector Vaccine.
  • Based on Application, market is studied across Allergy, Infectious Diseases, and Oncology.
  • Based on End-User, market is studied across Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical Companies.
  • Based on Delivery Method, market is studied across Gene Gun, Jet Injector, and Needle-Free Injection. The Needle-Free Injection is further studied across Biojector and Electroporation.
  • Based on Technology, market is studied across Electroporation Delivery, Gene Gun Delivery, and Liposome-Mediated Delivery.
  • Based on Therapeutic Area, market is studied across Allergy, Autoimmune Disorders, Cancer, and Infectious Diseases.
  • Based on Route of Administration, market is studied across Intradermal, Intramuscular, Intranasal, and Subcutaneous.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing need for rapid and scalable vaccine production methodologies
      • 5.1.1.2. Enhanced regulatory frameworks supporting the approval and commercialization of DNA vaccines
      • 5.1.1.3. Increasing collaboration between public and private sectors for vaccine development
      • 5.1.1.4. Expansion of vaccination programs in developing regions boosting market growth
    • 5.1.2. Restraints
      • 5.1.2.1. Low awareness and acceptance of DNA vaccine technology among healthcare professionals and patients
      • 5.1.2.2. Technical challenges in ensuring the stability and delivery of DNA vaccines in target cells
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising prevalence of infectious diseases necessitating the development of targeted DNA vaccines
      • 5.1.3.2. Development of personalized DNA vaccines offering tailor-made solutions for individual patient needs
      • 5.1.3.3. Advancements in delivery technologies enhancing the effectiveness and acceptance of DNA vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities in ensuring cold chain logistics for the distribution of DNA vaccines across different regions
      • 5.1.4.2. Barriers to market entry for new players due to high research and development costs in the DNA vaccine industry
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. DNA Vaccine Market, by Type

  • 6.1. Introduction
  • 6.2. Plasmid DNA Vaccine
  • 6.3. Recombinant Protein Vaccine
  • 6.4. Viral Vector Vaccine

7. DNA Vaccine Market, by Application

  • 7.1. Introduction
  • 7.2. Allergy
  • 7.3. Infectious Diseases
  • 7.4. Oncology

8. DNA Vaccine Market, by End-User

  • 8.1. Introduction
  • 8.2. Academic & Research Institutes
  • 8.3. Contract Research Organizations
  • 8.4. Pharmaceutical Companies

9. DNA Vaccine Market, by Delivery Method

  • 9.1. Introduction
  • 9.2. Gene Gun
  • 9.3. Jet Injector
  • 9.4. Needle-Free Injection
    • 9.4.1. Biojector
    • 9.4.2. Electroporation

10. DNA Vaccine Market, by Technology

  • 10.1. Introduction
  • 10.2. Electroporation Delivery
  • 10.3. Gene Gun Delivery
  • 10.4. Liposome-Mediated Delivery

11. DNA Vaccine Market, by Therapeutic Area

  • 11.1. Introduction
  • 11.2. Allergy
  • 11.3. Autoimmune Disorders
  • 11.4. Cancer
  • 11.5. Infectious Diseases

12. DNA Vaccine Market, by Route of Administration

  • 12.1. Introduction
  • 12.2. Intradermal
  • 12.3. Intramuscular
  • 12.4. Intranasal
  • 12.5. Subcutaneous

13. Americas DNA Vaccine Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific DNA Vaccine Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa DNA Vaccine Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. Astellas Pharma Inc.
  • 3. AstraZeneca plc
  • 4. Bioject Medical Technologies Inc.
  • 5. Emergent BioSolutions
  • 6. ExcellGene SA
  • 7. Genentech, Inc.
  • 8. GeneOne Life Science, Inc.
  • 9. GeoVax Labs, Inc.
  • 10. Immunomic Therapeutics, Inc.
  • 11. Inovio Pharmaceuticals, Inc.
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Novartis AG
  • 15. OncoSec Medical Incorporated
  • 16. Profectus BioSciences, Inc.
  • 17. TechnoVax Inc.
  • 18. Vaccibody AS
  • 19. Vaxess Technologies Inc.
  • 20. Vical Incorporated

LIST OF FIGURES

  • FIGURE 1. DNA VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. DNA VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DNA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DNA VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DNA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DNA VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DNA VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DNA VACCINE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DNA VACCINE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DNA VACCINE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DNA VACCINE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS DNA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS DNA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES DNA VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES DNA VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. DNA VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. DNA VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DNA VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DNA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DNA VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DNA VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DNA VACCINE MARKET SIZE, BY PLASMID DNA VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DNA VACCINE MARKET SIZE, BY RECOMBINANT PROTEIN VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DNA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DNA VACCINE MARKET SIZE, BY ALLERGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DNA VACCINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DNA VACCINE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DNA VACCINE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DNA VACCINE MARKET SIZE, BY JET INJECTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DNA VACCINE MARKET SIZE, BY BIOJECTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION DELIVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN DELIVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DNA VACCINE MARKET SIZE, BY LIPOSOME-MEDIATED DELIVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DNA VACCINE MARKET SIZE, BY ALLERGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DNA VACCINE MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL DNA VACCINE MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL DNA VACCINE MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL DNA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL DNA VACCINE MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL DNA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES DNA VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 284. POLAND DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 292. QATAR DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 300. RUSSIA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 308. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 316. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 324. SPAIN DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 329. SPAIN DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 330. SPAIN DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 332. SWEDEN DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 333. SWEDEN DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 334. SWEDEN DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 335. SWEDEN DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 336. SWEDEN DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 337. SWEDEN DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 338. SWEDEN DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 339. SWEDEN DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 340. SWITZERLAND DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 341. SWITZERLAND DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 342. SWITZERLAND DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 344. SWITZERLAND DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 346. SWITZERLAND DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 348. TURKEY DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 349. TURKEY DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 350. TURKEY DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 351. TURKEY DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 352. TURKEY DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 353. TURKEY DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 354. TURKEY DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 355. TURKEY DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 356. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 357. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 358. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 359. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 360. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 361. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 362. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 363. UNITED ARAB EMIRATES DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 364. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 365. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 366. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 367. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 368. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY NEEDLE-FREE INJECTION, 2018-2030 (USD MILLION)
  • TABLE 369. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 370. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 371. UNITED KINGDOM DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 372. DNA VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 373. DNA VACCINE MARKET, FP